AxelOng
2021-11-08
Wow another drug coming out
Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨2.2%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":844034187,"tweetId":"844034187","gmtCreate":1636376332630,"gmtModify":1636376333027,"author":{"id":4089463306606890,"idStr":"4089463306606890","authorId":4089463306606890,"authorIdStr":"4089463306606890","name":"AxelOng","avatar":"https://static.tigerbbs.com/8eaa7b50259b0329b74e09bc501ecd38","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow another drug coming out </p></body></html>","htmlText":"<html><head></head><body><p>Wow another drug coming out </p></body></html>","text":"Wow another drug coming out","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/844034187","repostId":1141245956,"repostType":2,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://www.laohu8.com/m/news/1141245956?lang=zh_CN&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨2.2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p><p><blockquote>再生元股价在盘前交易中上涨2.</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p><p><blockquote>再生元制药公司周一表示，在后期试验中使用该药物后的两到八个月内，单剂量的抗体鸡尾酒将感染COVID-19的风险降低了81.6%。</blockquote></p><p> The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p><p><blockquote>美国国立卫生研究院赞助的COVID预防网络单克隆抗体工作负责人迈伦·科恩(Myron Cohen)表示，结果表明，抗体疗法REGEN-COV有可能提供针对COVID-19感染的持久免疫力。</blockquote></p><p> Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p><p><blockquote>该公司表示，这种免疫力对于免疫功能低下的人和对疫苗没有反应的人尤其重要。</blockquote></p><p> The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p><p><blockquote>该疗法此前显示，在给药后的第一个月内风险降低了81.4%。</blockquote></p><p> During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p><p><blockquote>Regeneron表示，在8个月的评估期间，REGEN-COV组没有因COVID-19住院的病例，但安慰剂组记录了6起此类事件。</blockquote></p><p> The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p><p><blockquote>美国卫生监管机构于7月扩大了REGEN-COV的授权，使其能够用作接触感染者的人以及在疗养院或监狱等环境中处于此类暴露高风险的人的预防性治疗。</blockquote></p><p> It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p><p><blockquote>去年11月，它在美国获得授权，用于治疗轻度至中度COVID-19患者。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨2.2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨2.2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-08 20:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p><p><blockquote>再生元股价在盘前交易中上涨2.</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p><p><blockquote>再生元制药公司周一表示，在后期试验中使用该药物后的两到八个月内，单剂量的抗体鸡尾酒将感染COVID-19的风险降低了81.6%。</blockquote></p><p> The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p><p><blockquote>美国国立卫生研究院赞助的COVID预防网络单克隆抗体工作负责人迈伦·科恩(Myron Cohen)表示，结果表明，抗体疗法REGEN-COV有可能提供针对COVID-19感染的持久免疫力。</blockquote></p><p> Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p><p><blockquote>该公司表示，这种免疫力对于免疫功能低下的人和对疫苗没有反应的人尤其重要。</blockquote></p><p> The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p><p><blockquote>该疗法此前显示，在给药后的第一个月内风险降低了81.4%。</blockquote></p><p> During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p><p><blockquote>Regeneron表示，在8个月的评估期间，REGEN-COV组没有因COVID-19住院的病例，但安慰剂组记录了6起此类事件。</blockquote></p><p> The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p><p><blockquote>美国卫生监管机构于7月扩大了REGEN-COV的授权，使其能够用作接触感染者的人以及在疗养院或监狱等环境中处于此类暴露高风险的人的预防性治疗。</blockquote></p><p> It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p><p><blockquote>去年11月，它在美国获得授权，用于治疗轻度至中度COVID-19患者。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":782,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/844034187"}
精彩评论